Inhibition of capillary repair in proliferative glomerulonephritis results in persistent glomerular inflammation with glomerular sclerosis.
The pathological process of glomerulonephritis (GN) includes glomerular capillary damage, and vascular endothelial growth factor (VEGF) has an important role in glomerular capillary repair in GN. We examined the effect of inhibition of glomerular capillary repair after capillary injury in GN. Experimental Thy-1 GN was induced in rats that were divided into two groups: rats that received anti-VEGF neutralizing antibody (50 μg per 100 g body weight per day) and those treated with the vehicle from day 2 to day 9. We assessed the renal function and histopathology serially until week 6. Rats of the Thy-1 GN group showed diffuse glomerular mesangiolysis with ballooning destruction of the capillary network by day 3. VEGF(164) protein levels increased in the damaged glomeruli during days 5 to 10, and endothelial-cell proliferation increased with capillary repair in the vehicle-injected group. Proliferative GN resolved subsequently with decreased mesangial hypercellularity, and recovery of most of the glomeruli to the normal structure was evident by week 6. In contrast, administration of anti-VEGF antibody significantly decreased endothelial-cell proliferation and capillary repair in glomeruli by week 2. Thereafter, glomerular mesangial-cell proliferation and activation continued with persistent infiltration of macrophages. At week 6, segmental glomerular sclerosis developed with mesangial matrix accumulation and proteinuria. Deposition of type I collagen was also noted in sclerotic lesions. We conclude that impaired capillary repair was the underlying mechanism in the prolongation of glomerular inflammation in proliferative GN and in the development of glomerular sclerosis. Capillary repair has an important role in the recovery of glomerular damage and in the resolution of proliferative GN.
Masuda
Yukinari
Y
Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.
Shimizu
Akira
A
Kataoka
Mitue
M
Arai
Takashi
T
Ishikawa
Arimi
A
Du
Xuanyi
X
Saito
Sabine Kyoko
SK
Aki
Kaoru
K
Nagasaka
Shinya
S
Mii
Akiko
A
Fujita
Emiko
E
Fukuda
Yuh
Y
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D057134:Antibodies, Neutralizing / Q000276:immunology; D002196:Capillaries / Q000473:pathology / Q000503:physiopathology; D002452:Cell Count; D049109:Cell Proliferation; D004730:Endothelium, Vascular / Q000473:pathology; D015432:Glomerulonephritis, Membranoproliferative / Q000276:immunology / Q000473:pathology / Q000503:physiopathology*; D007249:Inflammation; D007518:Isoantibodies / Q000276:immunology; D007677:Kidney Function Tests; D007678:Kidney Glomerulus / Q000098:blood supply* / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D008264:Macrophages / Q000276:immunology / Q000473:pathology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012038:Regeneration; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology
D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D007518:Isoantibodies; D042461:Vascular Endothelial Growth Factor A; C035678:anti-Thy antibody; C467498:vascular endothelial growth factor A, rat